Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Selective identification of secreted and transmembrane breast cancer markers using Escherichia coli ampicillin secretion trap.

Ferguson DA, Muenster MR, Zang Q, Spencer JA, Schageman JJ, Lian Y, Garner HR, Gaynor RB, Huff JW, Pertsemlidis A, Ashfaq R, Schorge J, Becerra C, Williams NS, Graff JM.

Cancer Res. 2005 Sep 15;65(18):8209-17.

2.

MMP13 is potentially a new tumor marker for breast cancer diagnosis.

Chang HJ, Yang MJ, Yang YH, Hou MF, Hsueh EJ, Lin SR.

Oncol Rep. 2009 Nov;22(5):1119-27.

PMID:
19787229
3.

Coordinately up-regulated genes in ovarian cancer.

Hough CD, Cho KR, Zonderman AB, Schwartz DR, Morin PJ.

Cancer Res. 2001 May 15;61(10):3869-76.

4.

E. coli selection of human genes encoding secreted and membrane proteins based on cDNA fusions to a leaderless beta-lactamase reporter.

Tan R, Jiang X, Jackson A, Jin P, Yang J, Lee E, Duggan B, Stuve LL, Fu GK.

Genome Res. 2003 Aug;13(8):1938-43.

5.

Systematic identification and molecular characterization of genes differentially expressed in breast and ovarian cancer.

Dahl E, Sadr-Nabavi A, Klopocki E, Betz B, Grube S, Kreutzfeld R, Himmelfarb M, An HX, Gelling S, Klaman I, Hinzmann B, Kristiansen G, Grützmann R, Kuner R, Petschke B, Rhiem K, Wiechen K, Sers C, Wiestler O, Schneider A, Höfler H, Nährig J, Dietel M, Schäfer R, Rosenthal A, Schmutzler R, Dürst M, Meindl A, Niederacher D.

J Pathol. 2005 Jan;205(1):21-8.

PMID:
15586368
6.

Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.

Bignotti E, Tassi RA, Calza S, Ravaggi A, Romani C, Rossi E, Falchetti M, Odicino FE, Pecorelli S, Santin AD.

Gynecol Oncol. 2006 Nov;103(2):405-16.

PMID:
16725184
7.

cDNA microarray analysis of inflammatory breast cancer signatures.

Laere SJ, Vermeulen PB, Dirix LY.

Methods Mol Biol. 2009;512:71-98. doi: 10.1007/978-1-60327-530-9_6.

PMID:
19347274
8.

Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer.

Dahl E, Kristiansen G, Gottlob K, Klaman I, Ebner E, Hinzmann B, Hermann K, Pilarsky C, Dürst M, Klinkhammer-Schalke M, Blaszyk H, Knuechel R, Hartmann A, Rosenthal A, Wild PJ.

Clin Cancer Res. 2006 Jul 1;12(13):3950-60.

9.

Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer in a screen for signal sequence encoding proteins.

Esseghir S, Kennedy A, Seedhar P, Nerurkar A, Poulsom R, Reis-Filho JS, Isacke CM.

Clin Cancer Res. 2007 Jun 1;13(11):3164-73.

10.
11.

Identification of transmembrane proteins as potential prognostic markers and therapeutic targets in breast cancer by a screen for signal sequence encoding transcripts.

Esseghir S, Reis-Filho JS, Kennedy A, James M, O'Hare MJ, Jeffery R, Poulsom R, Isacke CM.

J Pathol. 2006 Dec;210(4):420-30.

PMID:
17054309
12.

Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach.

Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, Cohen P, Lidereau R, Bieche I.

Endocr Relat Cancer. 2006 Dec;13(4):1109-20.

13.

cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.

Villeneuve DJ, Hembruff SL, Veitch Z, Cecchetto M, Dew WA, Parissenti AM.

Breast Cancer Res Treat. 2006 Mar;96(1):17-39.

PMID:
16322897
14.

Identification of transmembrane protein in prostate cancer by the Escherichia coli ampicillin secretion trap: expression of CDON is involved in tumor cell growth and invasion.

Hayashi T, Oue N, Sakamoto N, Anami K, Oo HZ, Sentani K, Ohara S, Teishima J, Matsubara A, Yasui W.

Pathobiology. 2011;78(5):277-84. doi: 10.1159/000329588.

PMID:
21849809
15.

Novel breast cancer biomarkers identified by integrative proteomic and gene expression mapping.

Ou K, Yu K, Kesuma D, Hooi M, Huang N, Chen W, Lee SY, Goh XP, Tan LK, Liu J, Soon SY, Bin Abdul Rashid S, Putti TC, Jikuya H, Ichikawa T, Nishimura O, Salto-Tellez M, Tan P.

J Proteome Res. 2008 Apr;7(4):1518-28. doi: 10.1021/pr700820g.

PMID:
18318472
16.

Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer.

Bektas N, Haaf At, Veeck J, Wild PJ, Lüscher-Firzlaff J, Hartmann A, Knüchel R, Dahl E.

BMC Cancer. 2008 Feb 6;8:42. doi: 10.1186/1471-2407-8-42.

17.

Large isoform of MRJ (DNAJB6) reduces malignant activity of breast cancer.

Mitra A, Fillmore RA, Metge BJ, Rajesh M, Xi Y, King J, Ju J, Pannell L, Shevde LA, Samant RS.

Breast Cancer Res. 2008;10(2):R22. doi: 10.1186/bcr1874.

18.

The search for secreted proteins in prostate cancer by the Escherichia coli ampicillin secretion trap: expression of NBL1 is highly restricted to the prostate and is related to cancer progression.

Hayashi T, Sentani K, Oue N, Ohara S, Teishima J, Anami K, Sakamoto N, Matsubara A, Yasui W.

Pathobiology. 2013;80(2):60-9. doi: 10.1159/000341396.

PMID:
22948749
19.

Expression profiling of nucleotide metabolism-related genes in human breast cancer cells after treatment with 5-fluorouracil.

Behera RK, Nayak R.

Cancer Invest. 2009 Jun;27(5):561-7. doi: 10.1080/07357900802620802.

PMID:
19219653
20.

The role of the beta-lactamase signal sequence in the secretion of proteins by Escherichia coli.

Kadonaga JT, Gautier AE, Straus DR, Charles AD, Edge MD, Knowles JR.

J Biol Chem. 1984 Feb 25;259(4):2149-54.

Items per page

Supplemental Content

Support Center